You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

Details for New Drug Application (NDA): 209803


✉ Email this page to a colleague

« Back to Dashboard


NDA 209803 describes STEGLATRO, which is a drug marketed by Msd Sub Merck and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the STEGLATRO profile page.

The generic ingredient in STEGLATRO is ertugliflozin. Two suppliers are listed for this compound. Additional details are available on the ertugliflozin profile page.
Summary for 209803
Tradename:STEGLATRO
Applicant:Msd Sub Merck
Ingredient:ertugliflozin
Patents:1
Suppliers and Packaging for NDA: 209803
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
STEGLATRO ertugliflozin TABLET;ORAL 209803 NDA Merck Sharp & Dohme LLC 0006-5363 0006-5363-03 30 TABLET, FILM COATED in 1 BOTTLE (0006-5363-03)
STEGLATRO ertugliflozin TABLET;ORAL 209803 NDA Merck Sharp & Dohme LLC 0006-5363 0006-5363-06 90 TABLET, FILM COATED in 1 BOTTLE (0006-5363-06)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:Dec 19, 2017TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Sep 17, 2024
Regulatory Exclusivity Use:REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV
Patent:⤷  Sign UpPatent Expiration:Jul 13, 2030Product Flag?YSubstance Flag?YDelist Request?
Patented Use:AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength15MG
Approval Date:Dec 19, 2017TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Sep 17, 2024
Regulatory Exclusivity Use:REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.